Barosi, G., Hehlmann, R., & Reiter, A. (2015). Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: Consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia, 29(1), . https://doi.org/10.1038/leu.2014.250
Chicago-Zitierstil (17. Ausg.)Barosi, Giovanni, Rüdiger Hehlmann, und Andreas Reiter. "Clinical End Points for Drug Treatment Trials in BCR-ABL1-negative Classic Myeloproliferative Neoplasms: Consensus Statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)." Leukemia 29, no. 1 (2015). https://doi.org/10.1038/leu.2014.250.
MLA-Zitierstil (9. Ausg.)Barosi, Giovanni, et al. "Clinical End Points for Drug Treatment Trials in BCR-ABL1-negative Classic Myeloproliferative Neoplasms: Consensus Statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)." Leukemia, vol. 29, no. 1, 2015, https://doi.org/10.1038/leu.2014.250.